Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCH 58500 plus Chemotherapy in Ovarian Cancer
NCT00003880Phase 3Terminated
- Sponsor
- Merck & Co.
- Start
- Feb 1999
- Primary completion
- Aug 2001
- Modality
- Gene Editing, Gene Silencing, Adenoviral Vectors
01
Overview
A Phase 3 trial of AdCMVp53 in ovarian cancer, primary peritoneal cancer (PPC), sponsored by Merck & Co.. Started Feb 1999; status: terminated.
02
Drugs
AdCMVp53
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT00003880.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003880.